{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T14:11:12Z","timestamp":1773324672695,"version":"3.50.1"},"reference-count":117,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","cancertreatmentreviews.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.ctrv.2017.08.002","type":"journal-article","created":{"date-parts":[[2017,8,20]],"date-time":"2017-08-20T06:00:36Z","timestamp":1503208836000},"page":"1-11","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["Tracking MET de-addiction in lung cancer: A road towards the oncogenic target"],"prefix":"10.1016","volume":"60","author":[{"given":"S.","family":"Pilotto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Carbognin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Karachaliou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.C.","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Rosell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Tortora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Bria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2017.08.002_b0005","doi-asserted-by":"crossref","first-page":"252","DOI":"10.3322\/caac.21235","article-title":"Cancer treatment and survivorship statistics, 2014","volume":"64","author":"DeSantis","year":"2014","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ctrv.2017.08.002_b0010","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(16)00004-0","article-title":"Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)","author":"Barlesi","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2017.08.002_b0015","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/nature11404","article-title":"N. Comprehensive genomic characterization of squamous cell lung cancers","volume":"489","author":"Cancer Genome Atlas Research","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2017.08.002_b0020","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nature13385","article-title":"Comprehensive molecular profiling of lung adenocarcinoma","volume":"511","author":"Cancer Genome Atlas Research Network","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2017.08.002_b0025","doi-asserted-by":"crossref","DOI":"10.1111\/cas.12941","article-title":"Gene aberrations for precision medicine against lung adenocarcinoma","author":"Saito","year":"2016","journal-title":"Cancer Sci"},{"key":"10.1016\/j.ctrv.2017.08.002_b0030","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/nrc3205","article-title":"Targeting MET in cancer: rationale and progress","volume":"12","author":"Gherardi","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ctrv.2017.08.002_b0035","doi-asserted-by":"crossref","first-page":"4837","DOI":"10.1200\/JCO.2011.37.7929","article-title":"MET signaling pathway: a rational target for cancer therapy","volume":"29","author":"Appleman","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2017.08.002_b0040","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1200\/JCO.2012.43.9422","article-title":"MET as a possible target for non-small-cell lung cancer","volume":"31","author":"Sadiq","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2017.08.002_b0045","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s10555-007-9107-6","article-title":"The Met tyrosine kinase receptor in development and cancer","volume":"27","author":"Gentile","year":"2008","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.ctrv.2017.08.002_b0050","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1002\/gcc.20604","article-title":"Expression and mutational analysis of MET in human solid cancers","volume":"47","author":"Ma","year":"2008","journal-title":"Genes Chromosom Cancer"},{"key":"10.1016\/j.ctrv.2017.08.002_b0055","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1097\/JTO.0b013e3182417e44","article-title":"MET signaling: novel targeted inhibition and its clinical development in lung cancer","volume":"7","author":"Feng","year":"2012","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2017.08.002_b0060","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1200\/JCO.2015.64.2777","article-title":"Impaired c-Met receptor degradation mediated by MET exon 14 mutations in non-small-cell lung cancer","volume":"34","author":"Awad","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2017.08.002_b0065","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1158\/2159-8290.CD-15-0285","article-title":"Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors","volume":"5","author":"Frampton","year":"2015","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ctrv.2017.08.002_b0070","first-page":"820","article-title":"MET exon 14 deletion (METex14): finally, a frequent-enough actionable oncogenic driver mutation in non-small cell lung cancer to lead MET inhibitors out of \u201c40 years of wilderness\u201d and into a clear path of regulatory approval","volume":"4","author":"Reungwetwattana","year":"2015","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.ctrv.2017.08.002_b0075","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1158\/2159-8290.CD-14-1467","article-title":"Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping","volume":"5","author":"Paik","year":"2015","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ctrv.2017.08.002_b0080","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1158\/2159-8290.CD-15-0769","article-title":"MET receptor juxtamembrane exon 14 alternative spliced variant: novel cancer genomic predictive biomarker","volume":"5","author":"Ma","year":"2015","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ctrv.2017.08.002_b0085","doi-asserted-by":"crossref","first-page":"631","DOI":"10.2217\/pgs.15.11","article-title":"MET: a new promising biomarker in non-small-cell lung carcinoma","volume":"16","author":"Perez-Ramirez","year":"2015","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.ctrv.2017.08.002_b0090","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1200\/JCO.2008.19.1635","article-title":"Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients","volume":"27","author":"Cappuzzo","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2017.08.002_b0095","first-page":"197","article-title":"High MET copy number and MET overexpression: poor outcome in non-small cell lung cancer patients","volume":"27","author":"Park","year":"2012","journal-title":"Histol Histopathol"},{"key":"10.1016\/j.ctrv.2017.08.002_b0100","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1097\/JTO.0000000000000620","article-title":"Profiling of oncogenic driver events in lung adenocarcinoma revealed MET mutation as independent prognostic factor","volume":"10","author":"Yeung","year":"2015","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2017.08.002_b0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.cllc.2016.01.005","article-title":"Prognostic impact of multiple clinicopathologic risk factors and c-MET overexpression in patients who have undergone resection of stage IB non-small-cell lung cancer","author":"Kim","year":"2016","journal-title":"Clin Lung Cancer"},{"issue":"30\u201338","key":"10.1016\/j.ctrv.2017.08.002_b0110","first-page":"e31","article-title":"Alterations of MET gene copy number and protein expression in primary non-small-cell lung cancer and corresponding nodal metastases","volume":"17","author":"Tran","year":"2016","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.ctrv.2017.08.002_b0115","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.3892\/mmr.2014.3071","article-title":"Expression of hepatocyte growth factor and c-Met in non-small-cell lung cancer and association with lymphangiogenesis","volume":"11","author":"Zhang","year":"2015","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.ctrv.2017.08.002_b0120","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-15-2061","article-title":"MET amplification and exon 14 splice site mutation define unique molecular subgroups of Non-small Cell Lung Carcinoma with poor prognosis","author":"Tong","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2017.08.002_b0125","doi-asserted-by":"crossref","unstructured":"Clav\u00e9 S, Dalmases A, Longar\u00f3n R, et al. 11P Prognostic impact of MET mutations in exon 14 and copy number alterations in a series of NSCLC patients. J Thoracic Oncol 11: S61.","DOI":"10.1016\/S1556-0864(16)30125-3"},{"key":"10.1016\/j.ctrv.2017.08.002_b0130","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.lungcan.2016.12.001","article-title":"A comprehensive analysis of clinical outcomes in lung cancer patients harboring a MET exon 14 skipping mutation compared to other driver mutations in an East Asian population","volume":"103","author":"Gow","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctrv.2017.08.002_b0135","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s13000-015-0362-5","article-title":"Improved diagnostics targeting c-MET in non-small cell lung cancer: expression, amplification and activation?","volume":"10","author":"Watermann","year":"2015","journal-title":"Diagn Pathol"},{"key":"10.1016\/j.ctrv.2017.08.002_b0140","doi-asserted-by":"crossref","first-page":"4427","DOI":"10.1021\/jm401427c","article-title":"Targeting receptor tyrosine kinase MET in cancer: small molecule inhibitors and clinical progress","volume":"57","author":"Cui","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.ctrv.2017.08.002_b0145","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.lungcan.2016.11.011","article-title":"The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable","volume":"103","author":"Reungwetwattana","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctrv.2017.08.002_b0150","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1158\/0008-5472.CAN-12-3256","article-title":"Cytotoxic activity of tivantinib (ARQ 197) is not due solely to c-MET inhibition","volume":"73","author":"Katayama","year":"2013","journal-title":"Can Res"},{"key":"10.1016\/j.ctrv.2017.08.002_b0155","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1200\/JCO.2012.43.3383","article-title":"Phase II and biomarker study of the dual MET\/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma","volume":"31","author":"Choueiri","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2017.08.002_b0160","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1158\/2159-8290.CD-11-0175","article-title":"Durable complete response of metastatic gastric cancer with anti-Met therapy followed by resistance at recurrence","volume":"1","author":"Catenacci","year":"2011","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ctrv.2017.08.002_b0165","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/S1470-2045(14)70023-3","article-title":"Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study","volume":"15","author":"Iveson","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2017.08.002_b0170","doi-asserted-by":"crossref","first-page":"4105","DOI":"10.1200\/JCO.2012.47.4189","article-title":"Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer","volume":"31","author":"Spigel","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2017.08.002_b0175","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.2353\/ajpath.2010.100217","article-title":"Co-activation of epidermal growth factor receptor and c-MET defines a distinct subset of lung adenocarcinomas","volume":"177","author":"Matsubara","year":"2010","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ctrv.2017.08.002_b0180","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1200\/JCO.2016.69.2160","article-title":"Results from the phase III randomized trial of onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIB or IV non-small-cell lung cancer: METLung","volume":"35","author":"Spigel","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2017.08.002_b0185","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.cllc.2016.05.011","article-title":"Efficacy and safety results from a phase II, placebo-controlled study of onartuzumab plus first-line platinum-doublet chemotherapy for advanced squamous cell non-small-cell lung cancer","volume":"18","author":"Hirsch","year":"2017","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.ctrv.2017.08.002_b0190","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.cllc.2016.09.013","article-title":"Efficacy and safety of onartuzumab in combination with first-line bevacizumab- or pemetrexed-based chemotherapy regimens in advanced non-squamous non-small-cell lung cancer","volume":"18","author":"Wakelee","year":"2017","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.ctrv.2017.08.002_b0195","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.1200\/JCO.2010.34.0570","article-title":"Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer","volume":"29","author":"Sequist","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2017.08.002_b0200","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1200\/JCO.2014.60.7317","article-title":"Phase III multinational, randomized, double-blind, placebo-controlled study of tivantinib (ARQ 197) plus erlotinib versus erlotinib alone in previously treated patients with locally advanced or metastatic nonsquamous non-small-cell lung cancer","volume":"33","author":"Scagliotti","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2017.08.002_b0205","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1093\/annonc\/mdv288","volume":"26","author":"Yoshioka","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2017.08.002_b0210","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1016\/S1470-2045(16)30561-7","article-title":"Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial","volume":"17","author":"Neal","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2017.08.002_b0215","first-page":"8001","article-title":"Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer (NSCLC)","volume":"32","author":"Camidge","year":"2014","journal-title":"ASCO Meet Abstracts"},{"key":"10.1016\/j.ctrv.2017.08.002_b0220","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1097\/JTO.0b013e31821528d3","article-title":"Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification","volume":"6","author":"Ou","year":"2011","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2017.08.002_b0225","doi-asserted-by":"crossref","first-page":"4803","DOI":"10.1200\/JCO.2011.35.4928","article-title":"MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib","volume":"29","author":"Lennerz","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2017.08.002_b0230","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1200\/JCO.2011.38.4586","article-title":"Rapid radiographic and clinical improvement after treatment of a MET-amplified recurrent glioblastoma with a mesenchymal-epithelial transition inhibitor","volume":"30","author":"Chi","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2017.08.002_b0235","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1126\/science.1141478","article-title":"MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling","volume":"316","author":"Engelman","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.ctrv.2017.08.002_b0240","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1038\/nm.3388","article-title":"The quest to overcome resistance to EGFR-targeted therapies in cancer","volume":"19","author":"Chong","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2017.08.002_b0245","doi-asserted-by":"crossref","unstructured":"Sequist LV, Waltman BA, Dias-Santagata D et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011; 3: 75ra26.","DOI":"10.1126\/scitranslmed.3002003"},{"key":"10.1016\/j.ctrv.2017.08.002_b0250","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1158\/1078-0432.CCR-12-2246","article-title":"Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers","volume":"19","author":"Yu","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2017.08.002_b0255","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1097\/JTO.0000000000000516","article-title":"Multi-institutional oncogenic driver mutation analysis in lung adenocarcinoma: the lung cancer mutation consortium experience","volume":"10","author":"Sholl","year":"2015","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2017.08.002_b0260","doi-asserted-by":"crossref","first-page":"e000063","DOI":"10.1136\/esmoopen-2016-000063","article-title":"Phase II study of erlotinib plus tivantinib (ARQ 197) in patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer just after progression on EGFR-TKI, gefitinib or erlotinib","volume":"1","author":"Azuma","year":"2016","journal-title":"ESMO Open"},{"key":"10.1016\/j.ctrv.2017.08.002_b0265","doi-asserted-by":"crossref","DOI":"10.1007\/s00280-017-3283-z","article-title":"A phase Ib\/II study of cabozantinib (XL184) with or without erlotinib in patients with non-small cell lung cancer","author":"Wakelee","year":"2017","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ctrv.2017.08.002_b0270","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.jtho.2016.01.022","article-title":"Combined Pan-HER and ALK\/ROS1\/MET inhibition with dacomitinib and crizotinib in advanced non-small cell lung cancer: results of a phase I study","volume":"11","author":"Janne","year":"2016","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2017.08.002_b0275","doi-asserted-by":"crossref","unstructured":"Wu X, Kim D, Felip E, et al. Phase (Ph) II safety and efficacy results of a single-arm ph ib\/II study of capmatinib (INC280) + gefitinib in patients (pts) with EGFR-mutated (mut), cMET-positive (cMET+) non-small cell lung cancer (NSCLC). Abstract 9020. In 2016 ASCO Annual Meeting.","DOI":"10.1200\/JCO.2016.34.15_suppl.9020"},{"key":"10.1016\/j.ctrv.2017.08.002_b0280","first-page":"9070","article-title":"A randomized, open-label, phase 2 study of emibetuzumab plus erlotinib (LY+E) and emibetuzumab monotherapy (LY) in patients with acquired resistance to erlotinib and MET diagnostic positive (MET Dx+) metastatic NSCLC","volume":"34","author":"Camidge","year":"2016","journal-title":"ASCO Meet Abstracts"},{"key":"10.1016\/j.ctrv.2017.08.002_b0285","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.cllc.2016.06.008","article-title":"Soluble c-Met levels correlated with tissue c-Met protein expression in patients with advanced non-small-cell lung cancer","volume":"18","author":"Gao","year":"2017","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.ctrv.2017.08.002_b0290","doi-asserted-by":"crossref","first-page":"39535","DOI":"10.18632\/oncotarget.9425","article-title":"Plasma dynamic monitoring of soluble c-Met level for EGFR-TKI treatment in advanced non-small cell lung cancer","volume":"7","author":"Gao","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ctrv.2017.08.002_b0295","doi-asserted-by":"crossref","first-page":"51311","DOI":"10.18632\/oncotarget.9697","article-title":"The coexistence of MET over-expression and an EGFR T790M mutation is related to acquired resistance to EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer","volume":"7","author":"Gou","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ctrv.2017.08.002_b0300","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.canlet.2016.07.021","article-title":"Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment","volume":"380","author":"Shi","year":"2016","journal-title":"Cancer Lett"},{"key":"10.1016\/j.ctrv.2017.08.002_b0305","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2017.02.020","article-title":"Tolerable and effective combination of full-dose crizotinib and osimertinib targeting MET amplification sequentially emerging after T790M positivity in EGFR-mutant non-small cell lung cancer","author":"York","year":"2017","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2017.08.002_b0310","first-page":"6272","article-title":"C-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions","volume":"63","author":"Ma","year":"2003","journal-title":"Can Res"},{"key":"10.1016\/j.ctrv.2017.08.002_b0315","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1158\/0008-5472.CAN-04-2650","article-title":"Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer","volume":"65","author":"Ma","year":"2005","journal-title":"Can Res"},{"key":"10.1016\/j.ctrv.2017.08.002_b0320","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1158\/0008-5472.CAN-05-2749","article-title":"Somatic mutations lead to an oncogenic deletion of met in lung cancer","volume":"66","author":"Kong-Beltran","year":"2006","journal-title":"Can Res"},{"key":"10.1016\/j.ctrv.2017.08.002_b0325","doi-asserted-by":"crossref","first-page":"19457","DOI":"10.1016\/S0021-9258(17)32190-7","article-title":"Identification of a novel type of alternative splicing of a tyrosine kinase receptor. Juxtamembrane deletion of the c-met protein kinase C serine phosphorylation regulatory site","volume":"269","author":"Lee","year":"1994","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ctrv.2017.08.002_b0330","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/onc.2012.551","article-title":"Cbl-independent degradation of Met: ways to avoid agonism of bivalent Met-targeting antibody","volume":"33","author":"Lee","year":"2014","journal-title":"Oncogene"},{"key":"10.1016\/j.ctrv.2017.08.002_b0335","doi-asserted-by":"crossref","first-page":"9632","DOI":"10.1128\/MCB.25.21.9632-9645.2005","article-title":"Met\/Hepatocyte growth factor receptor ubiquitination suppresses transformation and is required for Hrs phosphorylation","volume":"25","author":"Abella","year":"2005","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.ctrv.2017.08.002_b0340","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S1097-2765(01)00378-1","article-title":"Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein","volume":"8","author":"Peschard","year":"2001","journal-title":"Mol Cell"},{"key":"10.1016\/j.ctrv.2017.08.002_b0345","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/sj.bjc.6603884","article-title":"Downstream signalling and specific inhibition of c-MET\/HGF pathway in small cell lung cancer: implications for tumour invasion","volume":"97","author":"Ma","year":"2007","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2017.08.002_b0350","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1111\/j.1349-7006.2008.00916.x","article-title":"Met gene copy number predicts the prognosis for completely resected non-small cell lung cancer","volume":"99","author":"Okuda","year":"2008","journal-title":"Cancer Sci"},{"key":"10.1016\/j.ctrv.2017.08.002_b0355","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1097\/JTO.0b013e3181913e0e","article-title":"Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers","volume":"4","author":"Onozato","year":"2009","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2017.08.002_b0360","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1101\/gr.145144.112","article-title":"The transcriptional landscape and mutational profile of lung adenocarcinoma","volume":"22","author":"Seo","year":"2012","journal-title":"Genome Res"},{"key":"10.1016\/j.ctrv.2017.08.002_b0365","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2016.06.004","article-title":"Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations","author":"Schrock","year":"2016","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2017.08.002_b0370","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.lungcan.2015.10.028","article-title":"Responses to the multitargeted MET\/ALK\/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation","volume":"90","author":"Jorge","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctrv.2017.08.002_b0375","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1200\/JCO.2015.62.0674","article-title":"Next-generation sequencing of pulmonary sarcomatoid carcinoma reveals high frequency of actionable MET gene mutations","volume":"34","author":"Liu","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2017.08.002_b0380","doi-asserted-by":"crossref","first-page":"e113","DOI":"10.1097\/JTO.0000000000000645","article-title":"MET 14 deletion in sarcomatoid non-small-cell lung cancer detected by next-generation sequencing and successfully treated with a MET inhibitor","volume":"10","author":"Lee","year":"2015","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2017.08.002_b0385","doi-asserted-by":"crossref","first-page":"96","DOI":"10.21037\/atm.2016.01.12","article-title":"Mutations at the splice sites of exon 14 of MET gene: a new target for sarcomatoid carcinomas?","volume":"4","author":"Wislez","year":"2016","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.ctrv.2017.08.002_b0390","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1200\/JCO.2015.63.4600","article-title":"MET Exon 14 mutations in non-small-cell lung cancer are associated with advanced age and stage-dependent MET genomic amplification and c-Met overexpression","volume":"34","author":"Awad","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2017.08.002_b0395","doi-asserted-by":"crossref","DOI":"10.1634\/theoncologist.2015-0510","article-title":"MET Exon 14 skipping in non-small cell lung cancer","author":"Heist","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.ctrv.2017.08.002_b0400","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.lungcan.2017.02.008","article-title":"MET exon 14 skipping mutation in triple-negative pulmonary adenocarcinomas and pleomorphic carcinomas: an analysis of intratumoral MET status heterogeneity and clinicopathological characteristics","volume":"106","author":"Kwon","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctrv.2017.08.002_b0405","doi-asserted-by":"crossref","first-page":"e101","DOI":"10.1016\/j.cllc.2015.01.009","article-title":"Response to crizotinib in a patient with lung adenocarcinoma harboring a MET splice site mutation","volume":"16","author":"Jenkins","year":"2015","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.ctrv.2017.08.002_b0410","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1097\/JTO.0000000000000491","article-title":"MET-mutated NSCLC with major response to crizotinib","volume":"10","author":"Mendenhall","year":"2015","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2017.08.002_b0415","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1097\/JTO.0000000000000478","article-title":"MET mutation associated with responsiveness to crizotinib","volume":"10","author":"Waqar","year":"2015","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2017.08.002_b0420","doi-asserted-by":"crossref","DOI":"10.1007\/s10637-016-0332-0","article-title":"A never-smoker lung adenocarcinoma patient with a MET exon 14 mutation (D1028N) and a rapid partial response after crizotinib","author":"Mahjoubi","year":"2016","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.ctrv.2017.08.002_b0425","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1200\/JCO.2008.20.4859","article-title":"The \u201clazarus response\u201d in treatment-naive, poor performance status patients with non-small-cell lung cancer and epidermal growth factor receptor mutation","volume":"27","author":"Langer","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2017.08.002_b0430","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2016.01.017","article-title":"Lazarus-type response to crizotinib in a patient with poor performance status and advanced MET Exon 14 skipping mutation-positive lung adenocarcinoma","author":"Shea","year":"2016","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2017.08.002_b0435","first-page":"108","article-title":"Efficacy and safety of crizotinib in patients (pts) with advanced MET exon 14-altered non-small cell lung cancer (NSCLC)","volume":"34","author":"Drilon","year":"2016","journal-title":"ASCO Meet Abstracts"},{"key":"10.1016\/j.ctrv.2017.08.002_b0440","doi-asserted-by":"crossref","first-page":"12783","DOI":"10.18632\/oncotarget.3727","article-title":"Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma","volume":"6","author":"Bria","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.ctrv.2017.08.002_b0445","doi-asserted-by":"crossref","first-page":"7580","DOI":"10.1158\/0008-5472.CAN-10-0436","article-title":"MET and KRAS gene amplification mediates acquired resistance to MET tyrosine kinase inhibitors","volume":"70","author":"Cepero","year":"2010","journal-title":"Can Res"},{"key":"10.1016\/j.ctrv.2017.08.002_b0450","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1158\/0008-5472.CAN-09-3620","article-title":"Acquired resistance of non-small cell lung cancer cells to MET kinase inhibition is mediated by a switch to epidermal growth factor receptor dependency","volume":"70","author":"McDermott","year":"2010","journal-title":"Can Res"},{"key":"10.1016\/j.ctrv.2017.08.002_b0455","doi-asserted-by":"crossref","DOI":"10.1158\/1535-7163.MCT-17-0104","article-title":"Genomic and molecular screenings identify different mechanisms for acquired resistance to MET inhibitors in lung cancer cells","author":"Gimenez-Xavier","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ctrv.2017.08.002_b0460","article-title":"Acquired MET Y1248H and D1246N mutations mediate resistance to MET inhibitors in non-small cell lung cancer","author":"Li","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2017.08.002_b0465","doi-asserted-by":"crossref","first-page":"e0136155","DOI":"10.1371\/journal.pone.0136155","article-title":"Mechanism of resistance and novel targets mediating resistance to EGFR and c-Met tyrosine kinase inhibitors in non-small cell lung cancer","volume":"10","author":"Botting","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ctrv.2017.08.002_b0470","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.lungcan.2015.10.020","article-title":"MET gene exon 14 deletion created using the CRISPR\/Cas9 system enhances cellular growth and sensitivity to a MET inhibitor","volume":"90","author":"Togashi","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctrv.2017.08.002_b0475","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1097\/JTO.0000000000000671","article-title":"Impact of concurrent PIK3CA mutations on response to EGFR tyrosine kinase inhibition in EGFR-mutant lung cancers and on prognosis in oncogene-driven lung adenocarcinomas","volume":"10","author":"Eng","year":"2015","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2017.08.002_b0480","doi-asserted-by":"crossref","DOI":"10.1038\/nrclinonc.2016.26","article-title":"Treating cancer with selective CDK4\/6 inhibitors","author":"O'Leary","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ctrv.2017.08.002_b0485","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1021\/jm501092z","article-title":"Small-molecule inhibitors of the MDM2-p53 protein-protein interaction (MDM2 Inhibitors) in clinical trials for cancer treatment","volume":"58","author":"Zhao","year":"2015","journal-title":"J Med Chem"},{"key":"10.1016\/j.ctrv.2017.08.002_b0490","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1016\/j.jtho.2016.06.013","article-title":"Acquired resistance to crizotinib in NSCLC with MET Exon 14 skipping","volume":"11","author":"Heist","year":"2016","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2017.08.002_b0495","doi-asserted-by":"crossref","DOI":"10.1038\/onc.2016.36","article-title":"Preclinical and clinical evaluation of MET functions in cancer cells and in the tumor stroma","author":"Finisguerra","year":"2016","journal-title":"Oncogene"},{"key":"10.1016\/j.ctrv.2017.08.002_b0500","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/nature14407","article-title":"MET is required for the recruitment of anti-tumoural neutrophils","volume":"522","author":"Finisguerra","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2017.08.002_b0505","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nrd4406","article-title":"MET inhibitors start on road to recovery","volume":"13","author":"Garber","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.ctrv.2017.08.002_b0510","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1038\/modpathol.2015.63","article-title":"Clinicopathologic analysis of programmed cell death-1 and programmed cell death-ligand 1 and 2 expressions in pulmonary adenocarcinoma: comparison with histology and driver oncogenic alteration status","volume":"28","author":"Koh","year":"2015","journal-title":"Mod Pathol"},{"key":"10.1016\/j.ctrv.2017.08.002_b0515","doi-asserted-by":"crossref","first-page":"26845","DOI":"10.18632\/oncotarget.15839","article-title":"PD-L1 expression and its relationship with oncogenic drivers in non-small cell lung cancer (NSCLC)","volume":"8","author":"Jiang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ctrv.2017.08.002_b0520","doi-asserted-by":"crossref","first-page":"8512","DOI":"10.1200\/JCO.2017.35.15_suppl.8512","article-title":"PD-L1 expression and response to immunotherapy in patients with MET exon 14-altered non-small cell lung cancers (NSCLC)","volume":"35","author":"Sabari","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2017.08.002_b0525","doi-asserted-by":"crossref","first-page":"9017","DOI":"10.1200\/JCO.2016.34.15_suppl.9017","article-title":"Total mutation burden (TMB) in lung cancer (LC) and relationship with response to PD-1\/PD-L1 targeted therapies","volume":"34","author":"Spigel","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2017.08.002_b0530","doi-asserted-by":"crossref","first-page":"8511","DOI":"10.1200\/JCO.2017.35.15_suppl.8511","article-title":"Impact of MET inhibitors on survival among patients (pts) with MET exon 14 mutant (METdel14) non-small cell lung cancer (NSCLC)","volume":"35","author":"Awad","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2017.08.002_b0535","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","article-title":"Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR","volume":"362","author":"Maemondo","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2017.08.002_b0540","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1470-2045(09)70364-X","article-title":"Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial","volume":"11","author":"Mitsudomi","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2017.08.002_b0545","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2017.08.002_b0550","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial","volume":"13","author":"Rosell","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2017.08.002_b0555","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1200\/JCO.2012.44.2806","article-title":"Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations","volume":"31","author":"Sequist","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2017.08.002_b0560","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1214886","article-title":"Crizotinib versus chemotherapy in advanced ALK-positive lung cancer","volume":"368","author":"Shaw","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2017.08.002_b0565","first-page":"782","article-title":"First-line crizotinib in ALK-positive lung cancer","volume":"372","author":"Solomon","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2017.08.002_b0570","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1038\/nm.3352","article-title":"Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer","volume":"19","author":"Vaishnavi","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2017.08.002_b0575","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1158\/2159-8290.CD-15-0443","article-title":"An oncogenic NTRK fusion in a patient with soft-tissue sarcoma with response to the tropomyosin-related kinase inhibitor LOXO-101","volume":"5","author":"Doebele","year":"2015","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ctrv.2017.08.002_b0580","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2016.02.021","article-title":"Dramatic response to combination erlotinib and crizotinib in a patient with advanced, EGFR-mutant lung cancer harboring De Novo MET amplification","author":"Gainor","year":"2016","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2017.08.002_b0585","first-page":"7514","article-title":"Activity of cabozantinib (XL184) in metastatic NSCLC: results from a phase II randomized discontinuation trial (RDT)","volume":"30","author":"Hellerstedt","year":"2012","journal-title":"ASCO Meet Abstracts"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737217301251?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737217301251?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T14:06:36Z","timestamp":1659362796000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737217301251"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":117,"alternative-id":["S0305737217301251"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2017.08.002","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tracking MET de-addiction in lung cancer: A road towards the oncogenic target","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2017.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}